Figure 1
The localization of mutations in the BCR-ABL kinase domain in imatinib-resistant CML. (A) Prior to starting a second tyrosine kinase inhibitor treatment. (B) Following treatment with a second tyrosine kinase inhibitor.
The localization of mutations in the BCR-ABL kinase domain in imatinib-resistant CML. (A) Prior to starting a second tyrosine kinase inhibitor treatment. (B) Following treatment with a second tyrosine kinase inhibitor.
